Dementia Drugs Market to Grow at a CAGR of 6.20% During 2026-2035, Driven by the Rising Prevalence of Dementia Across the 8 Major Markets

Dementia Drugs Market Overview

Dementia drugs are primarily used to manage symptoms associated with dementia, such as cognitive decline, memory loss, and behavioral changes. These medications work by regulating neurotransmitters, slowing disease progression, or alleviating symptoms, though they do not cure dementia. The market is growing due to the increasing prevalence of dementia globally, coupled with the rising aging population. Innovative treatments and therapies, alongside government support, are driving this market’s expansion. Additionally, advancements in research and drug development are enhancing the therapeutic landscape for dementia, presenting opportunities for market growth in the coming years.

Key Findings

• In July 2026, the FDA approved LEQEMBI IQLIK (lecanemab), a once-weekly subcutaneous autoinjector, as an initiation dose for early Alzheimer's disease, making it the first anti-amyloid therapy that can be given subcutaneously across the full course of treatment, with US launch planned for late August 2026.
• The anti-amyloid market is scaling quickly, with Leqembi global sales rising 74% year on year to USD 168 million in the first quarter of 2026, reflecting growing uptake of disease-modifying Alzheimer's therapies across the US, Japan, and China.
• Regulatory access widened across major markets in 2025 and 2026, with donanemab (Kisunla) approved in around 48 countries as of mid-2026, including a European Commission marketing authorisation granted in September 2025 after an earlier rejection.

Dementia Drugs Market Demand Drivers

The dementia drugs market is witnessing accelerated growth, driven by strategic acquisitions and therapeutic advancements in Alzheimer’s disease. In October 2024, AbbVie announced a USD 1.4 billion acquisition of Aliada Therapeutics, enhancing its neuroscience pipeline with ALIA-1758, an innovative antibody capable of crossing the blood-brain barrier to target amyloid beta. Additionally, in July 2024, the United States FDA approved Eli Lilly’s Kisunla, a groundbreaking therapy that demonstrated a 35% reduction in cognitive and functional decline during Phase 3 trials. These developments are significantly strengthening the market outlook and fostering continued investment in disease-modifying treatments.

Dementia Drugs Market Segmentation Analysis

Cholinesterase Inhibitors to Hold Significant Value for Segmentation by Drug Class

The types of drug classes involved in the market are MAO inhibitors, glutamate inhibitors, cholinesterase inhibitors, and others. Among these, cholinesterase inhibitors are expected to dominate due to their proven effectiveness in managing Alzheimer’s cognitive symptoms and strong regulatory support. For instance, in December 2023, Alpha Cognition announced FDA acceptance of its New Drug Application for ALPHA-1062, a new acetylcholinesterase inhibitor for mild-to-moderate Alzheimer’s disease, highlighting ongoing innovation in this class.

The market report also offers insights based on the indications, route of administration, end user, distribution channel, and region.

Dementia Drugs Market: Competitive Landscape

• In July 2026, Eisai and Biogen received FDA approval for LEQEMBI IQLIK (lecanemab), a subcutaneous autoinjector, as an initiation dose for early Alzheimer's disease, following the August 2025 approval of subcutaneous maintenance dosing. Eisai leads lecanemab's global development, with the two companies co-commercialising the therapy.
• In January 2025, Johnson & Johnson advanced two investigational Alzheimer's therapies, posdinemab and JNJ-2056, both targeting pathological tau proteins, under US FDA Fast Track designations, aiming to slow progression in early and preclinical disease.
• Other players involved in the market include Teva Pharmaceutical Industries Ltd., Aurobindo Pharma, Zydus Cadila, Eli Lilly and Company, Novartis AG, Biogen, Otsuka Pharmaceutical Co., Ltd., and Corium Inc.

Dementia Drugs Market Analysis by Region

North America is Projected to Lead the Market Share

The market segmentation by region includes the United States, Germany, France, Italy, Spain, the United Kingdom, Japan, and India. Among these, the United States is expected to lead the market share due to its high prevalence of dementia, robust healthcare infrastructure, and significant investment in pharmaceutical research. Supportive regulatory frameworks and ongoing clinical trials further drive innovation. 

Key Offerings of the Report

• The Expert Market Research report gives an overview of the market for Dementia Drugs for the period (2019-2025) and (2026-2035). 
• The report also offers historical (2019-2025) and forecast (2026-2035) market information for the indications, drug class, route of administration, end user, distribution channel, and region of the market.
• The report analyses the market dynamics, covering the key demand and price indicators in the market, along with providing an assessment of the SWOT and Porter’s Five Forces models.

About Us

Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which is constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.

EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.

Contact Us

Expert Market Research
Website: www.expertmarketresearch.com
Email: sales@expertmarketresearch.com
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790